Adenoviral TNF-α gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft

Gene Therapy

Volumn 5, Issue 3, 1998, Pages 293-300

  Staba, M J ^a   Mauceri, H J ^a   Kufe, D W ^b   Hallahan, D E ^a   Weichselbaum, R R ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Gene therapy; Malignant glioma; Radiation; Recombinant adenovirus; Tumoe necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GENE THERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION INJURY; TUMOR REGRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS;

EID: 0031951530     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300594     Document Type: Article

References (39)

1. Shrieve DC et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 1995; 36: 275-282.
2. Fine HA, Antman KH. High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience. (Review). Bone Marrow Transplant 1992; 10: 315-321.
3. Fine HA et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71: 2585-2597.
4. Levin VA et al Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for artaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990; 18: 321-324.
5. Deutsch M et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 1989; 16: 1389-1396.
6. Jolly D. Review article. Viral vector systems for gene therapy. Cancer Gene Ther 1994; 1: 5-64.
7. Fine HA. Prospects for gene therapy as an innovative approach to malignant gliomas. Perspect Neurol Surg 1994; 5: 115-127.
8. Avalosse B, Dupont F, Burney A. Gene therapy for cancer. Curr Opm Oncol 1995; 7: 94-100.
9. Chen SH, Shine HD, Goodman JC. Gene therapy for brain tumors: regression of experimental gliomas by adenovirusmediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054-3057.
10. Perez-Cruet MJ et al. Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res 1994; 39: 506-511.
11. Le Gal La Salle G et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 1993; 259: 988-990.
12. Weichselbaum RR et al. Radiation targeting of gene therapy preferentially radiosensitizes tumor cells. Cancer Res 1994; 54: 4266-4269.
13. Hallahan DE et al. Spatial and temporal control of gene therapy by ionizing radiation. Nature Med 1995; 1: 786-791.
14. Mauceri HJ et al. Tumor necrosis factor a gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res 1996; 56: 4311-4314.
15. Barbara JA et al. Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants. EMBO J 1994; 13: 843-850.
16. Lewis M et al. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA 1991; 88: 2830-2834.
17. Brouckaert P et al. Strategies to broaden the therapeutic margin of tumor necrosis factor. In: Fiers W, Buurman W (eds). Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance. Karger: Basel, 1993.
18. Nosoh Y et al. Antitumor effects of recombinant human tumor necrosis factor against human tumor xenografts transplanted into nude mice. Jpn J Surg 1987; 17: 51-54.
19. Malik STA et al. Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer 1984; 34: 263-267.
20. Shine N et al. Early metabolic response to tumor necrosis factor in mouse sarcoma: a phosphorous-31 nuclear magnetic resonance study. Cancer Res 1989; 49: 2123-2127.
21. Frater-Schroder M et al. Tumor necrosis factor, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987; 84: 5277-5281.
22. Fajardo LF et al. Dual role of tumor necrosis factor in angiogenesis. Am J Pathol 1992, 140: 539-544.
23. Sato N, Fukuda K, Nariuchi H, Sagara N. Tumor necrosis factor inhibiting angiogenesis in vitro J Natl Cancer Inst 1987; 79: 1383-1391.
24. Polunovsky VA et al. Induction of endothelial cell apoptosis by TXF: modulation by inhibitor of protein synthesis. Exp Cell Res 1994; 214: 584-594.
25. Bombeli T, Krsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89: 2429-2442.
26. Koga S et al. TNF modulates endothelial properties by decreasing cAMP Am J Physiol 1995; 268: C1104-C1113.
27. Nawroth P et al. Tumor necrosis factor/cachetin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med 1988; 168: 637-647.
28. Kirchofer D, Tschopp TB, Hadvary P, Baumgartner HR. Endothelial cells stimulated with tumor necrosis factor express varying amounts of tissue factor resulting in inhomogeneous fibrin deposition in a native blood flow system. J Clin Invest 1994; 93: 2073-2083.
29. Sporn IA, Rubin P, Marder VJ, Wagner DD. Irradiation induces release of von Willebrand protein from endothelial cells in culture. Blood 1984; 64: 567-570
30. Tsao C, Ward WF. Acute radiation effects on the content and release of plasminogen activator activity in cultured aortic endothelial cells. Radiat Res 1985; 101: 394-401.
31. Eissner G et al. Critical involvement of transmembrane tumor necrosis factor in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. Blood 1995; 86: 4184-4193.
32. Vischer UM, Jornot L, Wollheim CB, Theler JM. Reactive oxygen intermediates induce regulated secretion of von Willebrand fac- tor from cultured human vascular endothelial cells. Blood 1995; 85: 3164-3172.
33. Jourdan A et al. Experimental thrombosis model induced by free radicals. Application to aspirin and other different substances. Thromb Res 1995; 79: 118-123.
34. Freeman SM et al The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
35. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics, 2nd edn. Appleton and Lange: Norwalk, CT, 1993.
36. Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. J Am Stat Assoc 1952; 47: 583-621.
37. McGrory WJ et al. A simple technique for the rescue of early region I mutations into adenovirus type 5. Virology 1988; 163. 614-617.
38. Collett D. Modeling Survival Data in Medical Research. Chapman and Hall: London, 1994.
39. Montgomery D Design and Analysis of Experiments, 3rd edn. John Wiley and Sons: New York, 1991.